THAMEUS

SU2

Description

We are revolutionizing newborn screening by identifying over 165 serious and treatable genetic diseases in newborns, offering a chance for early intervention. Our supplementary test to existing screening is aimed at parents concerned about ensuring comprehensive medical care for their child, in collaboration with maternity hospitals and with medical prescrition. Our solution, validated in nearly 7.000 newborns, has proven its acceptability, feasibility, and usufulness through a publication in Nature Medicine as well as in other scientific journals.

Hall

HWL2025

Booth number

SU2

Business sector

Medical Supplies & Equipment

Website

www.babydetect.be